Summary
In two patients receivingl-asparaginase therapy, severe acute pancreatitis complicated by disseminated intravascular coagulation (DIC) developed. In both cases it was successfully treated with continuous infusion of a synthetic protease inhibitor, nafamostat mesilate. In this report, we briefly discuss the clinical efficacy of the synthetic protease inhibitor in treating such cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ando K, Maekawa T (1987) Treatment of DIC (in Japanese). Gendai Iryo (Tokyo) 19: 237
Aoyama T, Ino Y, Ozeki M, et al. (1984) Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35: 203
Bertolone SJ, Fuenfer MM, Groff DB, Patel CC (1982) Delayed pancreatic pseudocyst formation. Cancer 50: 2964
Caniano DA, Browne AF, Boles ET (1985) Pancreatic pseudocyst complicating treatment of acute lymphoblastic leukemia. J Pediatr Surg 20: 452
Cox AG, Armitage P, Hogg R, et al. (1980) Morbidity of acute pancreatitis; the effect of aprotinin and glucagon. Gut 21: 334
Fujii S, Hitomi Y (1981) New synthetic inhibitors of Clr, Cl esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 661: 342
Greenstein R, Nogeire C, Ohnuma T, Greenstein A (1979) Management of asparaginase-induced hemorrhagic pancreatitis complicated by pseudocyst. Cancer 43: 718
Haskel CM, Canellos GP, Leventhal BG, et al. (1969)l-Asparaginase. Therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281: 1028
Hitomi Y, Ikari N, Fujii S (1985) Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15: 164
Imrie CW, Benjamin IS, Ferguson JC, et al. (1978) A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 65: 337
Iwaki M, Ozeki M, Sato T, et al. (1984) Pharmacological studies of FUT-175, nafamostat mesilate. II. Effects on experimental acute pancreatitis. Folia Pharmacol Jpn 84: 363
Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T (1986) Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzyme and experimental acute pancreatitis in rats. Jpn J Pharmacol 41: 155
Kosaki G, Ogawa M, Ishida M, et al. (1984) Clinical evaluation of FUT-175, protease inhibitor, on acute pancreatitis. Dig Med (Tokyo) 1: 528
Land VJ, Sutow WW, Frenbach DJ, Lane DM, Williams TE (1972) Toxicity ofl-asparaginase in children with advanced leukemia. Cancer 30: 339
McLean R, Martin S, Lam-Po-Tang PRL (1982) Fatal case ofl-asparaginase-induced pancreatitis. Lancet 1: 1401
Oettgen HF, Stephenson PA, Schwartz MK, et al. (1969) Toxicity ofE. coli l-asparaginase in man. Cancer 25: 253
Ohno H, Kambayashi J, Chang SW, Kosaki G (1981) FOY: [Ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine protease inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 24: 445
Pitney WR, Phadke KP, Dean S (1980) Antithrombin III deficiency during asparaginase therapy. Lancet 1: 493
Priest JR, Ramsay NKC, Bennett AJ, Krivit W, Edson JR (1982) The effect ofl-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 100: 990
Reaman GH, Ladisch S, Echelberger C, Poplack DG (1980) Improved treatment results in the management of single and multiple relapse of acute lymphoblastic leukemia. Cancer 45: 3090
Satake K, Koh I, Nishiwaki H, Umeyama K (1985) Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. Digestion 32: 99
Shibata A, Takahashi H, Aoki N, et al. (1989) Nafamostat mesilate as a therapy for disseminated intravascular coagulation. Thromb Haemost 62: 371 (Abstract)
Steer ML, Meldolesi J, Figarella C (1984) Pancreatitis: the role of lysosomes. Dig Dis Sci 29: 934
Takahashi H, Takizawa S, Tatewaki W, et al. (1989) Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulation. Thromb Haemost 62: 372 (Abstract)
Takeuchi T, Takebe T, Sato T, et al. (1984) Clinical evaluation of FUT-175 (nafamostat mesilate) on pancreatitis, a doubleblind controlled study with gabexate mesilate. Dig Med (Tokyo) 1: 255
Tallal L, Tan C, Oettgen H, et al. (1970)E. coli l-asparaginase in the treatment of leukemia and solid tumor in 131 children. Cancer 25: 306
Thompson AG (1968) Proteinase inhibitors in experimental and clinical pancreatitis. Ann NY Acad Sci 146: 540
Vellenga E, Broekmans AW, Kluft C (1985) Thrombotic complications duringl-asparaginase related to protein C deficiency? Thromb Haemost 53: 443
Weetman RM, Baehner RL (1974) Latent onset of clinical pancreatitis in children receivingl-asparaginase therapy. Cancer 34: 780
Whitecar JP, Bodey GP, Harris JE, Freireich EJ (1970)l-Asparaginase. N Engl J Med 282: 732
Yoshikawa T, Murakami M, Furukawa Y, Kato H, Takemura S, Kondo M (1984) Effect of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats. Haemostasis 13: 374
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murakawa, M., Okamura, T., Shibuya, T. et al. Use of a synthetic protease inhibitor for the treatment ofl-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation. Ann Hematol 64, 249–252 (1992). https://doi.org/10.1007/BF01738305
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01738305